OA REMS
Compliance
made
Simple
On October 31st, 2024, the U.S. Food and Drug Administration (FDA) announced approval of a modification to the Opioid Analgesic Risk Evaluation and Mitigation Strategy (OA REMS), advancing a consumer mail back drug disposal option. The modification will require that manufacturers participating in the OA REMS Program will have to begin providing pre-paid drug mail back envelopes upon request to outpatient and community pharmacies and other dispensers of opioid analgesics by March 31, 2025.
The modification in OA REMS will only require manufacturers to make mail back envelopes available to outpatient and community pharmacies upon request.
DisposeRx has developed a comprehensive strategic solution requiring minimal effort and cost while attaining maximum benefit for the manufacturer.
The result will ensure that patients have access to opioid analgesics in their pain management regimen and are educated about available methods to safely dispose of unused medications.
OA REMS Compliance can be as simple as four easy steps.
ProjectMailback is the industry preferred solution that leaves the details of program development and implantation up to us. With a carefully constructed program tailored to all OA REMs manufacturers, we will manage all the requirements of the modifications to OA REMs for you.
With the deadline approaching, please contact us below so we can get begin working with you on your new OA REMs program.
For Manufacturer and Pharmacy Interest
With the 180 day deadline quickly approaching, we encourage you to contact us for our turn-key FDA compliant impactful and creative plan to prevent drug overdoses and reduce deaths.
For manufacturer or pharmacy interest, fill out the form to the right or call +1 (844) 456-1600 to be contacted within one business day.